<DOC>
	<DOCNO>NCT00078962</DOCNO>
	<brief_summary>This phase I trial study side effect best dose GTI-2040 gemcitabine treat patient metastatic unresectable solid tumor . Drugs use chemotherapy , gemcitabine , work different way stop tumor cell divide stop grow die . GTI-2040 may stop growth tumor cell block enzymes necessary growth make tumor cell sensitive gemcitabine</brief_summary>
	<brief_title>GTI-2040 Gemcitabine Treating Patients With Metastatic Unresectable Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary I . Determine toxicity profile maximum tolerate dose GTI-2040 gemcitabine patient metastatic unresectable solid tumor . Secondary I . Determine pharmacokinetics pharmacodynamics regimen patient . OUTLINE : This open-label , dose-escalation study . Patients receive GTI-2040 IV continuously day 2-16 course 1 day 1-16 subsequent course gemcitabine IV 30 minute day 1 , 8 , 15 course 1 day 2 , 9 , 16 subsequent course . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos GTI-2040 gemcitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , 10 additional patient treat dose . PROJECTED ACCRUAL : Approximately 18-40 patient accrue study within 6-20 month .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically cytologically confirm solid tumor Metastatic unresectable disease standard curative palliative measure exist longer effective Measurable evaluable disease No known active progressive brain metastasis primary brain tumor Performance status ECOG 02 Performance status Karnofsky 60100 % More 12 week Hemoglobin &gt; 9 g/dL Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 2 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN ( 5 time ULN hepatic metastasis present ) Creatinine ≤ 2.0 mg/dL Creatinine clearance ≥ 50 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction attribute compound similar chemical biological composition study drug No ongoing active infection No psychiatric illness social situation would preclude study compliance No condition ( e.g. , dementia developmental delay ) would preclude give informed consent No concurrent uncontrolled illness would preclude study participation Prior biologic therapy allow No concurrent biologic therapy No concurrent immunotherapy No concurrent routine filgrastim ( GCSF ) sargramostim ( GMCSF ) Prior gemcitabine allow Prior investigational chemotherapy allow At least 4 week since prior chemotherapy ( 6 week mitomycin , carmustine , nitrosoureas ) recover No concurrent chemotherapy Concurrent hormonal therapy ( e.g. , luteinizing hormonereleasing hormone agonist ) prostate cancer allow At least 4 week since prior radiotherapy recover No prior radiotherapy 25 % bone marrow No concurrent radiotherapy Recovered prior surgery No concurrent investigational therapy No concurrent anticancer therapy No concurrent combination antiretroviral therapy HIVpositive patient No concurrent longterm oral anticoagulation therapy ( e.g. , warfarin ) Prophylactic warfarin maintain central venous access patency allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>